Skye Bioscience Highlights Nimacimab's Promise in Obesity Treatment, Anticipates Phase 2a Data
Skye Bioscience Inc. (NASDAQ:SKYE) is one of the best hot stocks to buy according to Wall Street analysts.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | DAFNA Capital Management Nathan Fischel | 2,046.032 | $252,000 | -12% | 0.19% |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$10.00 | 450,000 | $4,500,000.00 | 8,393,520 | 2024-03-13 | Filing | |
$2.31 | 5,206,074 | $12,026,030.94 | 7,943,520 | 2024-01-31 | Filing | |
$0.02 | 881,000 | $16,474.70 | 25,683,957 | 2023-08-29 | Filing | |
$0.02 | 881,000 | $16,474.70 | 41,554,828 | 2023-08-29 | Filing | |
$100,000.00 | 1,000,000 | $100,000,000,000.00 | 1,000,000 | 2020-08-07 | Filing |
Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$4.99 | 43,026 | $214,699.74 | 167,522 | 2024-11-18 | Filing | |
$5.55 | 190 | $1,054.50 | 210,548 | 2024-11-15 | Filing | |
$4.99 | 19,489 | $97,250.11 | 82,259 | 2024-11-18 | Filing | |
$5.55 | 85 | $471.75 | 101,748 | 2024-11-15 | Filing | |
$4.99 | 43,206 | $215,597.94 | 166,342 | 2024-11-18 | Filing |